Two-fold expression of Receptor tyrosine kinase 2 (ROR2) in Giant cell tumor of bone: outcome of a case-control study.

Abstract

Abstract Background Transmembrane proteins of the Wnt family and receptor tyrosine kinase (ROR1 and ROR2) suppression or overexpression has been implicated in the causation of cancers. We determined the expression of ROR2 among patients of Giant cell tumor of bone (GCT) by Quantitative PCR (qPCR). Methods In this case-control study, samples of GCT tumor tissue (cases) and bone from the tumor-free margin (controls) were subjected to (qPCR) in patients undergoing definitive treatment. The GCT patients were classified per radiologic classification and histologic grading. Results Eleven cases and controls consisting of six males and five females with a mean age of 33.18 ± 12.35 (20–50) years were included over the study period of 2 years. The median duration since diagnosis was 12 (IQR 9) months. There was a 2.51-fold change (upregulation of ROR2 expression in cases than controls which was significant ((0.00). There was an upregulation in the expression of ROR2 with tumor grades. However, it failed to reach statistical significance (Campanacci (P 0.05 cases and 0.84 controls), Jaffe (P 0.07 cases and 0.44 controls), and Enneking (0.07 cases and 0.44 controls). There was no significant effect of treatment with bisphosphonates (P 0.17) and Denosumab (P 0.75) on ROR2 expression. Conclusion GCT cases exhibit upregulation of ROR2 expression by more than two folds confirming its role in the causation of osteoclast-mediated bone destruction. ROR2 can be targeted for drug development in the treatment of GCT.